


IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Lindberg et al.
Patent No. : 6,875,872 B1
Issue Date : April 5, 2005
For : NEW COMPOUNDS
Examiner : Celia Chang
Group Art Unit : 1625

RECEIVED
CENTRAL FAX CENTER

APR 06 2005

CERTIFICATE OF TRANSMISSION UNDER 37 C.F.R. 1.8	
I hereby certify that this paper is being facsimile transmitted to the U.S. Patent and Trademark Office on April 6, 2005 at the facsimile number 703-872-9307.	
John M. Genova	32,224
Agent Name	PTO Reg. No.
	6 April 2005
Signature	Date of Signature

Attention: Office of Petitions

Mail Stop Petition

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PETITION UNDER 37 C.F.R. § 1.183
TO CORRECT ASSIGNEE'S NAME

Sir:

The referenced patent is a continuation of U.S. Patent Application Serial No. 09/187,277, filed November 6, 1998, abandoned, which is a continuation of U.S. Patent Application Serial No. 08/899,931, filed July 24, 1997, abandoned, which is a continuation application of U.S. Patent Application Serial No. 08/376,512 (the "512 application"), filed January 23, 1995, now US 5,714,504 (the "504 patent"), which is a continuation-in-part application of U.S. Patent Application Serial No. 08/256,174, filed June 28, 1994, now US 5,693,818, filed as PCT/SE94/00509, filed May 27, 1994.

An Assignment was filed in the priority CIP application, i.e., the '512 application, now the '504 patent (hereinafter the "Assignment"). The Assignment is from the inventors to Astra Aktiebolag. The Assignment was recorded on April 17, 1995 at Reel 7438, Frame 0120. A copy of each of the Assignment and the Notice of Recordation of the Assignment is enclosed. A change of corporate name from Astra Aktiebolag to AstraZeneca AB was recorded on September 25, 2000 at Reel 011219, Frame 0749. A copy of the Notice of Recordation of the name change is also enclosed.


The Assignment extends to any continuations of the '512 application and any patents issuing on such continuations. Accordingly, the Assignment extends to the referenced US 6,875,872. Therefore, the assignee of the referenced US 6,875,872 is AstraZeneca AB.

However, by inadvertence, the assignee's name was incompletely and erroneously furnished in item 3 of the Issue Fee Transmittal Form (PTOL-85B) as AstraZeneca rather than the correct and complete name AstraZeneca AB. Accordingly, it is hereby requested to waive 37 C.F.R. §3.81(a) to permit the complete and correct name of the assignee, AstraZeneca AB, to be provided after issuance of the referenced US 6,875,872.

Authorization is hereby given to charge the petition fee required by 37 C.F.R. §1.17(h) of \$130.00 as well any additional fee due in connection with this Petition to Deposit Account No. 23-1703.

Dated: 6 April 2005

Respectfully submitted,


John M. Genova
Reg. No. 32,224

Customer No. 07470
Attorney Direct Dial: (212) 819-8832